More efficient drug delivery system and formulation with less adverse effects are needed for the clinical application of broad-spectrum antineoplastic agent doxorubicin (DOX). Here we obtained outer-membrane vesicles (OMVs), a nano-sized proteoliposomes naturally released by Gram-negative bacteria, from attenuated
Klebsiella pneumonia
and prepared doxorubicin-loaded O0MVs (DOX-OMV). Confocal microscopy and
in vivo
distribution study observed that DOX encapsulated in OMVs was efficiently transported into NSCLC A549 cells. DOX-OMV resulted in intensive cytotoxic effects and cell apoptosis
in vitro
as evident from MTT assay, Western blotting and flow cytometry due to the rapid cellular uptake of DOX. In A549 tumor-bearing BALB/c nude mice, DOX-OMV presented a substantial tumor growth inhibition with favorable tolerability and pharmacokinetic profile, and TUNEL assay and H&E staining displayed extensive apoptotic cells and necrosis in tumor tissues. More importantly, OMVs’ appropriate immunogenicity enabled the recruitment of macrophages in tumor microenvironment which might synergize with their cargo DOX
in vivo
. Our results suggest that OMVs can not only function as biological nanocarriers for chemotherapeutic agents but also elicit suitable immune responses, thus having a great potential for the tumor chemoimmunotherapy.
The electrochemiluminescence (ECL) behavior of luminol on a nafion-nano-TiO(2) modified glassy carbon electrode (nafion-nano-TiO(2)--GCE) was studied. Two ECL peaks (ECL-1 and ECL-2) were found during cathodic potential scanning. ECL-1 at ca -0.4 V (vs Ag--AgCl reference electrode) came from the reaction between luminol and active oxygen anion produced at the GCE surface directly, while ECL-2 at ca -0.9 V (vs Ag--AgCl reference electrode) came from the reaction between luminol and the active oxygen anion catalyzed by TiO(2.) The possible mechanism for the generation of both ECL peaks has been proposed. The reproducibility of the ECL intensities on nafion-nano-TiO(2)--GCE at ECL-1 and ECL-2 was good, with relative standard deviations (n = 10) of 4.3 and 1.3%, respectively. The ECL-2 generated at the nafion-nano-TiO(2)--GCE surface was further developed to detect the dissolved oxygen, and a detection limit of 0.02 mg/L was achieved. The proposed method was applied to detect dissolved oxygen in water with satisfactory result.
Bisphenol A (BPA), a typical endocrine disruptor, is widely used as a key monomer in the packaging industry. Residual monomer can transfer from the package material to the food and thereby pose a risk to the health of the consumer, so determination of BPA migration is highly important for food safety control. In this study, a simple but sensitive electrochemiluminescence (ECL) biosensor, which combines the characteristics of high selectivity of an aptamer and high sensitivity of ECL, has been developed to detect BPA from package materials. The aptamer was immobilized on a gold electrode surface through Au-S interaction. The aptamer was then hybridized with complementary DNA (CDNA) to form double-stranded DNA (dsDNA). Ru(phen) can intercalate into the grooves of dsDNA and acts as an ECL indicator; high ECL intensity can therefore be detected from the electrode surface. In the presence of BPA, which can competitively bind with the aptamer owing to their high affinity, Ru(phen) is released from the electrode surface and the ECL of the system is decreased. The decreasing ECL signal has a linear relationship with BPA in the range of 0.1-100 pM with a detection limit of 0.076 pM. The developed biosensor has been applied to detect migration of BPA from different categories of canned drink with satisfactory results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.